

## Supplementary material

**Table S1:** Baseline characteristics

	<b>N = 213</b>
<b>Age (years)</b>	
<b>Mean (SD)</b>	50 (15)
<b>Range</b>	18-73
<b>Underlying disease, n (%)</b>	
<b>Acute leukemia</b>	141 (66)
<b>MDS</b>	28 (13)
<b>Non-Hodgkin lymphoma</b>	16 (8)
<b>Others</b>	28 (13)
<b>Conditioning intensity, n (%)</b>	
<b>Myeloablative</b>	106 (50)
<b>Reduced intensity</b>	107 (50)
<b>Conditioning regimen, n (%)</b>	
<b>Flu/Cy/TBI (13.2 Gy)</b>	69 (32)
<b>Cy/TBI (13.2 Gy)</b>	27 (13)
<b>Flu/Cy/TBI (2 Gy)</b>	97 (46)
<b>Others</b>	20 (9)
<b>GVHD prophylaxis, n (%)</b>	
<b>CNI + MMF</b>	155 (73)
<b>Sirolimus + MMF</b>	28 (13)
<b>CNI + Methotrexate</b>	22 (10)
<b>Others</b>	8 (4)

CNI: Calcineurin inhibitor; Cy: Cyclophosphamide; Flu: Fludarabine; MDS: Myelodysplastic syndrome; MMF: Mycophenolate mofetil; SD: Standard deviation; TBI: Total body irradiation

**Table S2:** Antibiotic exposures and CMV reactivation in univariate analysis

	<b>HR (95%CI)</b>	<b>P</b>
<b><i>Antibiotic exposures by day +14 (binary)</i></b>		
<b>Fluoroquinolones</b>	1.20 (0.55-2.60)	0.64
<b>Third or higher generation cephalosporins</b>	1.21 (0.76-1.93)	0.43
<b>Vancomycin</b>	1.84 (1.16-2.91)	0.01
<b>Piperacillin-Tazobactam</b>	0.88 (0.51-1.52)	0.65
<b>Carbapenems</b>	1.31 (0.81-2.14)	0.27
<b>Metronidazole</b>	1.08 (0.62-1.90)	0.78
<b>Clindamycin</b>	0.52 (0.24-1.14)	0.10
<b><i>Antibiotic exposures by day +100 (time-varying)</i></b>		
<b>Fluoroquinolones</b>	1.50 (0.47-2.84)	0.76
<b>Third or higher generation cephalosporins</b>	1.67 (0.92-3.02)	0.09
<b>Vancomycin</b>	2.06 (1.17-3.60)	0.01
<b>Piperacillin-Tazobactam</b>	0.81 (0.50-1.34)	0.42
<b>Carbapenems</b>	1.39 (0.90-2.15)	0.14
<b>Metronidazole</b>	0.92 (0.55-1.53)	0.74
<b>Clindamycin</b>	0.56 (0.27-1.16)	0.12